<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073812444607</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073812444607</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Communication</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Dysferlinopathy Presenting as Rhabdomyolysis and Acute Renal Failure</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Moody</surname>
<given-names>Shadé</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073812444607">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Mancias</surname>
<given-names>Pedro</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073812444607">1</xref>
<xref ref-type="corresp" rid="corresp1-0883073812444607"/>
</contrib>
</contrib-group>
<aff id="aff1-0883073812444607">
<label>1</label>Department of Pediatrics, Division of Child and Adolescent Neurology, University of Texas Medical School at Houston, Houston, TX, USA</aff>
<author-notes>
<corresp id="corresp1-0883073812444607">Pedro Mancias, MD, Department of Pediatrics, Division of Child and Adolescent Neurology, University of Texas-Medical School at Houston, 6431 Fannin St, Houston, TX 77030. Email: <email>Pedro.Mancias@uth.tmc.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>4</issue>
<fpage>502</fpage>
<lpage>505</lpage>
<history>
<date date-type="received">
<day>26</day>
<month>1</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>3</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Dysferlinopathies are a heterogeneous group of autosomal recessive muscle disorders resulting from defects or deficiencies in dysferlin. Reported phenotypes range from isolated hyperCKemia to muscular dystrophy. We present a 15-year-old male adolescent who was diagnosed with a dysferlinopathy after presenting with acute renal failure secondary to rhabdomyolysis.</p>
</abstract>
<kwd-group>
<kwd>dysferlin</kwd>
<kwd>dysferlinopathy</kwd>
<kwd>rhabdomyolysis</kwd>
<kwd>renal failure</kwd>
<kwd>creatine kinase</kwd>
<kwd>myoglobin</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Dysferlin is a transmembrane protein involved in calcium-mediated repair of the sarcolemma.<sup><xref ref-type="bibr" rid="bibr1-0883073812444607">1</xref>,<xref ref-type="bibr" rid="bibr2-0883073812444607">2</xref></sup> Patients with dysferlinopathies have defective skeletal muscle membrane repair that leads to the classic phenotypes of Miyoshi myopathy, limb girdle muscular dystrophy type 2B, and distal myopathy of the anterior tibialis.<sup><xref ref-type="bibr" rid="bibr1-0883073812444607">1</xref><xref ref-type="bibr" rid="bibr2-0883073812444607"/><xref ref-type="bibr" rid="bibr3-0883073812444607"/><xref ref-type="bibr" rid="bibr4-0883073812444607"/><xref ref-type="bibr" rid="bibr5-0883073812444607"/><xref ref-type="bibr" rid="bibr6-0883073812444607"/><xref ref-type="bibr" rid="bibr7-0883073812444607"/>–<xref ref-type="bibr" rid="bibr8-0883073812444607">8</xref></sup> An intermediate proximodistal phenotype, pseudometabolic myopathy, and isolated hyperCKemia have also been reported.<sup><xref ref-type="bibr" rid="bibr3-0883073812444607">3</xref><xref ref-type="bibr" rid="bibr4-0883073812444607"/><xref ref-type="bibr" rid="bibr5-0883073812444607"/>–<xref ref-type="bibr" rid="bibr6-0883073812444607">6</xref></sup> Rhabdomyolysis with acute renal failure, however, is a largely unrecognized presentation of dysferlin deficiency. We present a case of dysferlinopathy presenting as rhabdomyolysis with acute renal failure.</p>
<sec id="section1-0883073812444607">
<title>Case Report</title>
<p>A 15-year-old athletic African American boy with recently diagnosed hypertension treated with Omelsartan presented with a 3-day history of intermittent epigastric and flank pain relieved by lying down and with acetaminophen. He was previously evaluated at an outside facility emergency room where he was found to have elevated levels of creatinine and transaminases. On arrival to our facility, he was found to have rhabdomyolysis and pigment nephropathy requiring hemodialysis. He was an avid high school football and basketball player who lifted weights regularly. He denied postexercise fatigue, myalgia, cramping, paralysis, or past history of dark-colored urine. He denied use of illicit drugs, steroids, or herbal supplements. He had no significant family history. His physical examination revealed normal cranial nerve function, normal sensation, 2+ deep tendon reflexes, normal muscle tone and strength, well-defined musculature, and no myotonia. His initial creatine kinase was 381 89 units/L, and in 8 months of follow-up, his creatine kinase never decreased below 7000 units/L. Serum and urine myoglobin were elevated at 4841 and 3758 ng/mL, respectively. His creatinine peaked at over 12 mg/dL. Initial serum alanine aminotransferase and aspartate aminotransferase were 284 and 538 units/L, respectively. His initial serum potassium was normal but peaked at 6.7 mmol/L during his hospitalization. Serum lactate, pyruvate, plasma amino acids, urine organic acids, antinuclear antibody, complement components 3 and 4, and an acylcarnitine panel were all normal. An extensive infectious disease workup including tests for human immunodeficiency virus, cytomegalovirus IgG/IgM, Epstein-Barr IgG/IgM, hepatitis panel, mycoplasma IgG/IgM, influenza, parainfluenza, adenovirus, and RSV were all negative.</p>
<p>Electrocardiograms revealed normal sinus rhythm with transient T wave inversion in inferior and lateral leads on 2 electrocardiograms. Nerve conduction studies of the left arm and leg were normal. Electromyography revealed increased insertional activity and occasional fibrillations in the vastus lateralis, extensor digitorum communis, and L4 paraspinal muscles. These findings were suggestive of nonspecific irritability as seen with rhabdomyolysis. Short T1 inversion recovery (STIR) and T2 fat-suppressed magnetic resonance imaging (MRI) of the bilateral lower extremities revealed increased signal intensity in the quadriceps and hamstrings (illustrated in <xref ref-type="fig" rid="fig1-0883073812444607">Figure 1</xref>) as well as in the gastrocnemius muscles. These findings were consistent with an inflammatory process.</p>
<fig id="fig1-0883073812444607" position="float">
<label>Figure 1.</label>
<caption>
<p>Short T1 Inversion Recovery imaging of bilateral thighs with arrows showing areas of increased signal intensity in hamstrings and quadriceps muscles.</p>
</caption>
<graphic xlink:href="10.1177_0883073812444607-fig1.tif"/>
</fig>
<p>A muscle biopsy performed 4 months after his initial presentation revealed muscle fiber necrosis with phagocytosis and regeneration consistent with rhabdomyolysis, increased internal nuclei, and severe type 2 fiber predominance. Staining of the muscle for dystrophin, α-sarcoglycan, γ-sarcoglycan, β-dystroglycan, merosin, emerin, desmin, caveolin-3, and spectrin were all normal. Enzymatic evaluation of the muscle for phosphorylase A, phosphorylase B kinase, myoadenylate deaminase, phosphoglycerate kinase, phosphoglycerate mutase, lactate dehydrogenase, carnitine palmitoyltransferase, glycogen, and phosphofructokinase were all normal. Subsequent muscle staining for dysferlin revealed complete lack of dysferlin (<xref ref-type="fig" rid="fig2-0883073812444607">Figure 2</xref>). Dysferlin DNA sequencing revealed a guanine-to-adenine change at position IVS17-1 that is a disease-associated mutation with a predicted autosomal recessive inheritance. The DNA sequencing did not detect any abnormalities on the other allele. Western blot analysis of the patient’s monocytes revealed no detectable level of dysferlin.</p>
<fig id="fig2-0883073812444607" position="float">
<label>Figure 2.</label>
<caption>
<p>Muscle biopsy slides revealing complete absence of dysferlin staining with normal staining for merosin, dystrophin, β-dystroglycan, and γ-sarcoglycan.</p>
</caption>
<graphic xlink:href="10.1177_0883073812444607-fig2.tif"/>
</fig>
</sec>
<sec id="section2-0883073812444607">
<title>Discussion</title>
<p>The dysferlinopathies are a group of recessively inherited disorders resulting from deficiency in dysferlin, which is involved in calcium-mediated membrane repair.<sup><xref ref-type="bibr" rid="bibr1-0883073812444607">1</xref>,<xref ref-type="bibr" rid="bibr2-0883073812444607">2</xref></sup> The subsequent inability to effectively repair muscle membranes leads to a number of phenotypes ranging from an asymptomatic state to severe disability.<sup><xref ref-type="bibr" rid="bibr3-0883073812444607">3</xref>,<xref ref-type="bibr" rid="bibr4-0883073812444607">4</xref>,<xref ref-type="bibr" rid="bibr6-0883073812444607">6</xref></sup> The classic phenotypes include Miyoshi myopathy, limb girdle muscular dystrophy type 2B, and distal myopathy of the tibialis anterior.<sup><xref ref-type="bibr" rid="bibr1-0883073812444607">1</xref><xref ref-type="bibr" rid="bibr2-0883073812444607"/><xref ref-type="bibr" rid="bibr3-0883073812444607"/><xref ref-type="bibr" rid="bibr4-0883073812444607"/><xref ref-type="bibr" rid="bibr5-0883073812444607"/><xref ref-type="bibr" rid="bibr6-0883073812444607"/>–<xref ref-type="bibr" rid="bibr7-0883073812444607">7</xref>,<xref ref-type="bibr" rid="bibr9-0883073812444607">9</xref></sup> Miyoshi myopathy is a condition that typically starts in adolescence or young adulthood and is characterized by distal weakness and atrophy with onset in the gastrocnemius muscles.<sup><xref ref-type="bibr" rid="bibr4-0883073812444607">4</xref>,<xref ref-type="bibr" rid="bibr5-0883073812444607">5</xref></sup> Later involvement of the anterior leg compartment, pelvic, and distal upper extremity muscles can occur. Occasionally, myalgias and calf swelling without myoglobinuria can occur. Limb girdle muscular dystrophy type 2B is a slowly progressive muscular dystrophy with typical onset in late adolescence with predominant weakness of the pelvic girdle muscles with later involvement of the shoulder girdle muscles.<sup><xref ref-type="bibr" rid="bibr4-0883073812444607">4</xref>,<xref ref-type="bibr" rid="bibr5-0883073812444607">5</xref></sup> With time, involvement of the distal legs can also occur, causing foot drop. Distal myopathy of the tibialis anterior, also called distal anterior compartment myopathy, has initial involvement of the tibialis anterior but is otherwise similar to Miyoshi myopathy.<sup><xref ref-type="bibr" rid="bibr5-0883073812444607">5</xref><xref ref-type="bibr" rid="bibr6-0883073812444607"/>–<xref ref-type="bibr" rid="bibr7-0883073812444607">7</xref></sup> Isolated hyperCKemia, pseudometabolic myopathy, and a proximodistal phenotype with weakness of the proximal lower limbs and calf atrophy have been reported.<sup><xref ref-type="bibr" rid="bibr4-0883073812444607">4</xref><xref ref-type="bibr" rid="bibr5-0883073812444607"/><xref ref-type="bibr" rid="bibr6-0883073812444607"/>–<xref ref-type="bibr" rid="bibr7-0883073812444607">7</xref></sup></p>
<p>Although isolated hyperCKemia has been reported with dysferlinopathies, rhabdomyolysis with renal failure is a previously unreported presentation. Our patient presented with acute renal failure secondary to rhabdomyolysis and after an extensive evaluation was found to have a dysferlinopathy. A number of etiologies for rhabdomyolysis exist such as mitochondrial or metabolic myopathies, endocrinopathies, infections, drugs/toxins, local ischemia, excessive physical exertion, and trauma but dysferlinopathy is a largely unrecognized cause.<sup><xref ref-type="bibr" rid="bibr10-0883073812444607">10</xref></sup> A unique clinical feature within the scope of muscular dystrophies is that a number of patients with dysferlinopathies do not have muscle weakness upon presentation.<sup><xref ref-type="bibr" rid="bibr1-0883073812444607">1</xref></sup> As was the case with our patient who was an avid athlete, a number of these patients participate in sports or other strenuous physical activity without difficulty before the onset of their symptoms.<sup><xref ref-type="bibr" rid="bibr1-0883073812444607">1</xref>,<xref ref-type="bibr" rid="bibr5-0883073812444607">5</xref>,<xref ref-type="bibr" rid="bibr8-0883073812444607">8</xref>,<xref ref-type="bibr" rid="bibr10-0883073812444607">10</xref></sup> Physical exercise with subsequent muscle membrane damage may in fact trigger the onset of symptoms in these patients.<sup><xref ref-type="bibr" rid="bibr1-0883073812444607">1</xref></sup> A dysferlinopathy should be in the differential diagnosis in the appropriate setting when a patient presents with rhabdomyolysis and renal failure. The underlying defect in muscle membrane repair makes strenuous activity (which is associated with muscle membrane damage) risky in these patients as there is limited capacity for membrane repair. Athletes, in particular, should be cautioned against strenuous physical activity as this may hasten the progression of symptoms.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgment</title>
<p>Previously presented in abstract form at the Carrell-Krusen Neuromuscular Symposium, February 2009.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1-0883073812444607">
<label>Author Contributions</label>
<p>SM contributed to data collection and the first draft of the manuscript. PM participated in critical evaluation and revisions of the manuscript.</p>
</fn>
<fn fn-type="conflict" id="fn2-0883073812444607"><label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0883073812444607"><label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article. </p>
</fn>
<fn fn-type="other" id="fn4-0883073812444607"><label>Ethical Approval</label>
<p>The writing/research of this article did not require ethical approval.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073812444607">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacciottolo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Numitone</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Aurino</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Muscular dystrophy with marked dysferlin deficiency is consistently caused by primary dysferlin gene mutations</article-title>. <source>Eur J Hum Genet</source>. <year>2011</year>;<volume>19</volume>:<fpage>974</fpage>–<lpage>980</lpage>.</citation>
</ref>
<ref id="bibr2-0883073812444607">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Dysferlin and muscle membrane repair</article-title>. <source>Curr Opin Cell Biol</source>. <year>2007</year>;<volume>19</volume>:<fpage>409</fpage>–<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr3-0883073812444607">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okahashi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Asymptomatic sporadic dysferlinopathy presenting with elevation of serum creatine kinase, typical distribution of muscle involvement shown by MRI but not by CT</article-title>. <source>Intern Med</source>. <year>2008</year>;<volume>47</volume>:<fpage>305</fpage>–<lpage>307</lpage>.</citation>
</ref>
<ref id="bibr4-0883073812444607">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paradas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gonzalez-Quereda</surname>
<given-names>L</given-names>
</name>
<name>
<surname>De Luna</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>A new phenotype of dysferlinopathy with congenital onset</article-title>. <source>Neuromuscul Disord</source>. <year>2009</year>;<volume>19</volume>:<fpage>21</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr5-0883073812444607">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klinge</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Kress</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Late onset in dysferlinopathy widens the clinical spectrum</article-title>. <source>Neuromuscul Disord</source>. <year>2008</year>;<volume>18</volume>:<fpage>288</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr6-0883073812444607">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bassez</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Krahn</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Phenotypic study in 40 patients with dysferlin gene mutations high frequency of atypical phenotype</article-title>. <source>Arch Neurol</source>. <year>2007</year>;<volume>64</volume>:<fpage>1176</fpage>–<lpage>1182</lpage>.</citation>
</ref>
<ref id="bibr7-0883073812444607">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Illa</surname>
<given-names>I</given-names>
</name>
<name>
<surname>De Luna</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Domínguez-Perles</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Symptomatic dysferlin gene mutation carriers: characterization of two cases</article-title>. <source>Neurology</source>. <year>2007</year>;<volume>68</volume>:<fpage>1284</fpage>–<lpage>1289</lpage>.</citation>
</ref>
<ref id="bibr8-0883073812444607">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosales</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gastier-Foster</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Novel diagnostic features of dysferlinopathies</article-title>. <source>Muscle Nerve</source>. <year>2010</year>;<volume>42</volume>:<fpage>14</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr9-0883073812444607">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klinge</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Aboumousa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eagle</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>New aspects on patients affected by dysferlin deficient muscular dystrophy</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2010</year>;<volume>81</volume>:<fpage>946</fpage>–<lpage>953</lpage>.</citation>
</ref>
<ref id="bibr10-0883073812444607">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cervellin</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Comelli</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lippi</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features</article-title>. <source>Clin Chem Lab Med</source>. <year>2010</year>;<volume>48</volume>:<fpage>749</fpage>–<lpage>756</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>